Memorial Sloan-Kettering scientists, physicians, and administrators are developing and commercializing research discoveries to generate more-effective and affordable cancer treatments.
German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.
In his decade of leadership, Dr. Wittes helped to establish the Human Oncology and Pathogenesis Program, the Survivorship Initiative, the Quality of Care Initiative, and other key programs.
Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.
A new therapy tested in mouse models appears to harness neutrophils, a type of white blood cell, to effectively prevent the spread of breast cancer cells.
A surprising discovery has been made about how the cancer drug imatinib (Gleevec ®) works in treating blood cancers and gastrointestinal stromal tumors.
“This is a celebration about your journey to return to the life you want to have,” Adult Bone Marrow Transplant Center Chief Sergio Giralt told 200 survivors at a party packed with friends and caregivers.